

Higher Prevalence of Risk Alleles for Hyperuricemia Parallels Elevated Incidence of Gout and Growing Risk for Cardiovascular Diseases in a Hmong Population

Youssef Roman¹, Jenny Xiong¹, Kathleen Culhane-Pera², Robert Straka¹

¹Experimental and Clinical Pharmacology, College of Pharmacy, Minneapolis, MN, ²East Side Family Clinic, St. Paul, MN

Introduction

- Hyperuricemia (HU), (having a Serum Uric Acid [SUA] > 6mg/dL)⁽¹⁾ is a metabolic disorder associated with cardiovascular diseases and gout. HU can be exacerbated by medications and diet (Fig.1)⁽²⁾.
- The Hmong, a unique Asian population >60,000 in MN, have a 2-fold increased risk of gout compared to non-Hmong^(4,5).
- 35 % of renal stones in Hmong were composed of pure uric acid vs. 2% in non-Hmong⁽⁴⁾
- Studies of the genetic bases of HU have identified racial differences in the prevalence of gene variants associated with elevated SUA^(6,7).
- Central Research Question: **Does the prevalence of variant alleles associated with elevated SUA differ between Hmong and non-Hmong?**
- AIM 1:** to ascertain risk allele frequencies of 7 Single Nucleotide Polymorphisms (SNPs) within 4 key genes (TABLE 1) associated with SUA homeostasis (Fig.2)
- AIM 2:** to compare risk allele frequencies of those SNPs within Hmong subjects with HU versus normal SUA.
- Significance:** Knowledge of genetic basis for susceptibility to HU could serve as a basis for guiding a clinician's choice of drug therapy and/or intensive dietary counseling to mitigate this genetic based enhanced risk for HU.

Methods

Salivary DNA of 236 self-identified Hmong, was genotyped by Taqman or Sequenom iPLEX Gold method using Bruker Autoflex II MALDI/TOF mass spectrometer. Frequencies of risk allele associated with elevated SUA in Hmong were compared to (1) Caucasian (CEU) and (2) Han-Chinese (CHB) for four genes documented to be associated with HU using Hap-Map data⁽⁸⁾. HU vs. genotype was also evaluated within the Hmong using Chi-Square test or Fisher's exact test when appropriate. Mean SUA level vs. genotype was ascertained within the Hmong using one-way factor ANOVA. Bonferroni adjustment was used to account for multiple risk allele frequencies comparisons (critical value p<0.007 for significance).







TABLE (1)	Protein	Chr	Function
SLC2A9	GLUT 9	4	UA reabsorption/excretion
SLC22A12	URAT 1	11	UA reabsorption
ABCG2	BCRB	4	UA excretion
PDZK1	PDZK	1	Scaffolding protein for URAT1 function

TABLE (2)	Mean ± SD	Min	Max
Age (yrs.)	30.2 ± 15.4	18	85
Height- in	61.8 ± 4.5	44	73
Weight- lbs	150.89 ± 37.5	90	300
Uric Acid (UA) mg/dL	6.3 ± 1.7	3.5	11.4
Waist- inches			
Female (n=105)	33.3 ± 5.7	24.5	50.1
Male (n=132)	35.6 ± 5.4	26	51.5

TABLE (3)		Hmong		Han-Chinese (CHB) ⁸		P-Value	Caucasian (CEU) ⁸		P-Value
Gene (SNP)	Alleles*	Allele Count (%)		Allele Count (%)			Allele Count (%)		
SLC22A12 rs505802	C/T	297 (0.648)	161 (0.352)	204 (0.745)	70 (0.255)	0.0068	62 (0.27)	164 (0.73)	0.0001
ABCG2 rs2231142	G/T	293 (0.637)	167 (0.363)	194 (0.708)	80 (0.292)	0.059	201 (0.89)	25 (0.11)	0.0001
PDZK1 rs12129861	G/A	307 (0.673)	149 (0.327)	220 (0.803)	54 (0.197)	0.001	122 (0.54)	104 (0.46)	0.001
SLC2A9 rs3733591	T/C	265 (0.586)	187 (0.414)	190 (0.693)	84 (0.307)	0.005	43 (0.20)	175 (0.80)	0.0001
SLC2A9 rs11942223	T/C	452 (0.987)	6 (0.013)	89 (0.989)	1 (0.011)	0.652	97 (0.75)	33 (0.25)	0.001
SLC2A9 rs734553	T/G	459 (0.985)	7 (0.150)	273 (0.996)	1 (0.004)	0.269	167 (0.74)	59 (0.26)	0.0001
SLC2A9 rs1014290	A/G	317 (0.695)	139 (0.305)	161 (0.596)	109 (0.404)	0.0068	168 (0.74)	58 (0.26)	0.191

*Bold= risk allele



Results

- Mean (±SD) age of participants was 30.2 (15.4), and > 61% either overweight or obese with mean (±SD) SUA 6.3 (1.7) mg/dL (TABLE 2)
- All selected SNPs were in Hardy Weinberg (HW) equilibrium
- 6/7 SNPs showed a statistical significance difference in risk allele frequencies vs. Caucasian (CEU) Hap-Map data (TABLE 3)
- 4/7 SNPs showed a statistical significance difference in risk allele frequencies vs. Han-Chinese (CHB) Hap-Map data (TABLE 3)
- SNP by SNP analysis failed to show association with SUA levels (representative example, see Fig. 4)

Conclusions

- Risk allele frequencies of selected SNPs are not independent of race.
- Significant differences in risk alleles frequencies between the Hmong and non-Hmong may partly explain the genetic basis of high prevalence of gout in the Hmong.
- Risk alleles frequencies in Hmong vs. non-Hmong were consistent with the higher prevalence of gout
- Our sample size precludes a robust assessment of a significant association between genotype and [SUA].

Clinical Translation

- Our findings contribute to the validation of genetic based biomarkers capable of predicting an individual's risk for developing HU and/or gout. They may also explain the variability in response to urate lowering drugs thereby having an impact on patient care by:
- Identifying individuals with a genetic predisposition to developing HU and gout
 - Optimizing drug selection for patients with known CVD and with/or at risk for HU or gout
 - Continuing to decrease the economic and social burden of gout
 - Addressing the health disparity of gout within the Hmong (or other populations at risk)

Future Directions

Prospective assessment of a larger Hmong cohort is needed to quantify the impact of different genotypes of select UA transporters on baseline SUA and differential effectiveness of drugs that act via these same transporters. Prospective assessment of the impact of targeted dietary interventions or drug therapy reviews for genetically "at risk" populations

Disclosure

The authors of this poster have declared no conflict of interests

Acknowledgments

Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health Award Number UL1TR000114. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. University of Minnesota Program in Health Disparities Research PHDR2008-005 Biostatistical support from Jeremiah Menk M.S., CTSI, UMN

References

- Khanna, Dinesh, et al. "2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia." *Arthritis care & research* 64.10 (2012): 1431-1446.
- Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease. *Cleveland Clinic journal of medicine*. Jul 2008;75 Suppl 5:S13-16.
- Singh JA. Racial and gender disparities among patients with gout. *Current rheumatology reports*. Feb 2013;15(2):307.
- Portis, Andrew J., et al. "Rapid Communication: Stone Disease in the Hmong of Minnesota: Initial Description of a High-Risk Population." *Journal of endourology* 18.9 (2004): 853-857
- Portis AJ, Laliberte MT, P. Moua, M.K. Culhane-Pera, K.A. Maalouf, N.M. Sakhaee, K. High Prevalence of Gouty Arthritis Among the Hmong Population in Minnesota *Arthritis Care and Research* Submitted 2010.
- Kottgen A, Albrecht E, Teumer A, et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. *Nature genetics*. Feb 2013;45(2):145-154.
- Kolz M, Johnson T, Sanna S, et al. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. *PLoS genetics*. Jun 2009;5(6):e10005
- http://hapmap.ncbi.nlm.nih.gov/cgi-perl/gbrowse/hapmap28_B36/on 3/19/14

